Corbus Pharmaceuticals Holdings (CRBP) Restructuring Costs (2022)

Corbus Pharmaceuticals Holdings' (CRBP) quarterly Restructuring Costs came in at $5.0 million in Q2 2022.

Corbus Pharmaceuticals Holdings (CRBP) Restructuring Costs (2022) Analysis & Trends

Corbus Pharmaceuticals Holdings' Restructuring Costs history runs 1 years deep, the most recent figure standing at $5.0 million for Q2 2022.

On a quarterly basis, Restructuring Costs changed N/A year-over-year to $5.0 million in Q2 2022; TTM through Jun 2023 was $5.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $5.0 million, changed N/A from the prior year.
Restructuring Costs held at $5.0 million in Q2 2022 per CRBP's latest filing.
Across five years, Restructuring Costs topped out at $5.0 million in Q2 2022 and bottomed at $5.0 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Corbus Pharmaceuticals Holdings	164.14 Mn	136.33 Mn	-

Download Data

Date	Value
Jun 30, 2022	5.00 Mn